MANTLE CELL LYMPHOMA (MCL)

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…

This early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…

This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …

This phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…

This early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This phase 2 trial is testing a combination of two drugs—a CAR-T cell therapy (relmacabtagene autoleucel) and a PD-1 inhibitor (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma. The goal is to see if the combo can shrink tumors and improve survival. Participan…

This early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …

This study tests a combination of two drugs, pirtobrutinib (a pill) and rituximab (an infusion), in 50 adults newly diagnosed with a slow-growing form of mantle cell lymphoma. The goal is to see if this drug pair can shrink or control the cancer without the need for standard chem…

This study is testing a combination of three drugs—orelabrutinib, lisaftoclax, and rituximab—in people with untreated, high-risk mantle cell lymphoma (MCL). The goal is to see how well this treatment shrinks or eliminates cancer. The trial will enroll 25 participants and track re…

This study tests a combination of three drugs—pomalidomide, orelabrutinib, and zuberitamab—in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see if the treatment can reduce cancer cells to undetectable levels after six cycles. Participants who …

This study tests a combination of two drugs (orelabrutinib and rituximab) in people newly diagnosed with a type of blood cancer called mantle cell lymphoma that is not high-risk. Some participants may also receive a stem cell transplant using their own cells. The goal is to see h…

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…